期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

类风湿关节炎的生物制剂治疗 被引量：12

Biologic agents for rheumatoid arthritis treatment
下载PDF
导出
摘要 类风湿关节炎(rheum atoid arthritis,RA)是一种常见的致残性疾病,严重影响患者的生活质量。传统的RA药物治疗主要包括非甾体抗炎药、糖皮质激素以及慢作用药物,然而这些药物常常不能满意控制那些难治性RA患者的病情,最终导致关节进行性破坏。近年,由于多种生物制剂的出现,为治疗难治性RA带来了希望,这些生物制剂在控制风湿病情和改善生活质量方面发挥了重要作用。 Rheumatoid arthritis is a common disabling diease,seriously affecting the patients＇ quality of life.Traditional drugs treatment for rheumatoid arthritis include nonsteroid anti-inflammatory drugs,corticosteroids,and disease modifying antirheumatic drugs,however,these drugs are often not satisfied to control the condition of refractory rheumatoid arthritis,and resulting in severe joint damage.Recently,the emergence of multiple biological agents brought hope to the treatment of refractory rheumatoid arthritis patients.These agents play an important role in the control of rheumatic conditions and the improvement of quality of life in RA patients.
作者 陈龙 袁国华
机构地区 川北医学院风湿免疫研究所
出处 《实用医院临床杂志》 2011年第2期10-13,共4页 Practical Journal of Clinical Medicine
关键词 类风湿关节炎 生物制剂 治疗 Rheumatoial avthritis Biologic agents Tveatment
分类号 R593.22 [医药卫生—内科学]
  • 相关文献

参考文献10

  • 1Maini RN, Breedveld FC, Kalden JR, et al. Sustained improvement o- ver two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infix- imab and methotrexate[ J]. Arthritis Rheum,2004,50-1051-1065.
  • 2van Vollenhoven RF, Ernestam S, Geborek P, et al. Addition of inflix- imab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis( swefot tri-al) :l-year results of a randomised triM[ J]. Lancet,2009,374:459- 466.
  • 3van der Heijde D, Klareskog L, Singb A, et al. Patient reported out- comes in a trial of combination therapy with etanercept and metho- trexate for rheumatoid arthritis: the TEMPO trial[ J]. Ann Rheum Dis ,2005,65:328-334.
  • 4Breedveld FC, Weisman MH, Kavanaugh AF, et al. A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adali- mumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment [ J ]. Arthritis Rheum,2006,54(1 ) :26-37.
  • 5Schiff M, Pritchard C, Huffstutter JE, et al. The 6-month safety arid efficacy of abatacept in patients with rheumatoid arthritis who under- went a washout after anti-tumour necrosis factor therapy or were di- rectly switched to abatacept: the ARRIVE trial [ J ]. Ann Rheum Dis,2009,68 : 1708-1714.
  • 6Weinblatt ME, Keystone EC, Fnrst DE,et al. Adalimumab,a fully human anti-tumor necrosis factor ~monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant meth- otrexate : the ARMADA trial [ J ]. Arthritis Rheum, 2003,48 : 35 -45.
  • 7van der Heijde D, Klareskog L, Landewe R, et al. Diseae remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis [J]. Arthritis Rheum,2007,56(12) :3928-3939.
  • 8胡大伟,鲍春德,陈顺乐,古洁若,栗占国,孙凌云,韩星海,倪立青.重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗类风湿关节炎双盲随机多中心对照临床研究[J].中华风湿病学杂志,2005,9(11):664-668. 被引量：86
  • 9Jones G,Sebba A,Gu J,et al. Comparison of tocilizumab monoth~ra- py versus methotrexate monotherapy in patients with moderate to se- vere rheumatoid arthritis : The AMBITION study [ J ]. Ann Rheum Dis,2010,69( 1 ) :88-96.
  • 10Nishimoto N,Miyasaka N, Yamamoto K, et al. Study of active con- trolled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI) :sigrtifcant reduc- tion in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy [ J ]. Mod Rheumatol, 2009,19 (1) :12-19.

二级参考文献12

  • 1Feldmann M, Brennan FM, Maini RN. The role of cytokines in rheumatoid arthritis. Ann Rev Immunol, 1996, 14: 397-440.
  • 2Wooley PH, Dutcher J, Widmer MB, et al. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type Ⅱ collagen-induced arthritis in mice. J Immunol,1993, 151: 6602-6607.
  • 3Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum, 1995, 6: 727-735.
  • 4Felson DT, Anderson JJ, Boers M, et al. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum, 1995, 38:727-735.
  • 5American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum, 1996, 39: 713.
  • 6Cash JM, Klippel JH. Second-line drug therapy for rheumatoid arthritis. New Engl J Med, 1994, 330: 1369-1375.
  • 7Firestein GS, Zvaifler NJ. Anticytokine therapy in rheumatoid arthritis. New Engl J Med, 1997, 337: 195-197.
  • 8Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of Etanercept and methotrexate in patients with early rheumatoid arthritis. New Eng J Med, 2000, 343: 1586-1593.
  • 9Moreland LW, Cohen SB, Baumgartner SW, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol,2001, 28: 1238-1244.
  • 10Weinblatt ME, Kremer JM, Bankhurst A, et al. A trial of etanercept: a recombinant tumor necrosis factor receptor: Fc fusion protein in patients with rheumatoid arthritis receiving methotrexate.New Engl J Med, 1999, 340: 253-259.

共引文献85

同被引文献122

  • 1韩波,丁峰,李兴福,刘花香,王志杰.细胞毒类免疫抑制剂在类风湿关节炎治疗中的应用[J].山东医药,2004,44(28):65-66. 被引量：1
  • 2鲍春德.生物制剂治疗类风湿关节炎进展[J].实用医院临床杂志,2007,4(3):3-5. 被引量：5
  • 3李瑞,孟庆刚.类风湿性关节炎的临床治疗研究[J].中华中医药学刊,2007,25(7):1348-1352. 被引量：35
  • 4Arnett FC,Edworth SM,Bloch DA,et al.The American Rheumatism Association 1987 revised criteria for classification of rheumatoid arthrifts[J].Arthritis Rheum,1988,31:315-324.
  • 5Toussirot E,Wendling D.The use of TNF alpha blocking agents in rheumatoid arthritis:an update[J].Exp opin Pharmacother,2007,8:2089-107.
  • 6Del Rincon I, O'Leary DH, Freeman GL, et al. Acceleration of atherosclerosis during the course of rheumatoid arthritis [ J ]. Atherosclerosis, 2007,195 ( 2 ) : 354-360.
  • 7Arnett FC, Edworthy SM, Bloch DA,et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis [ J ]. Arthritis Rheum, 1988,31 : 315-324.
  • 8Yamashina A, Tomiyama H, Takeda K, et al. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement [ J ]. Hypertens Res,2002,25 (3) :359-364.
  • 9Mallika V, Goswami B, Rajappa M. et al. Athemsclemsis pathophysiology and the role of novel risk factors : a clinicobiochemical perspective [ J ]. Angiology. 2007,58 ( 5 ) : 513-522.
  • 10Yambe M, Tomiyama H, Hirayama Y, et al. Arterial stiffening as a possible risk factor for both atherosclerosis and diastolic heart failure [J]. Hypertens Res ,2004,27:625-631.

引证文献12

二级引证文献76

实用医院临床杂志
2011年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部